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ess: kchapman@ca.inteSummary The present bibliographic review shows that patients considered to
have mild asthma often suffer impairment in quality of life (QoL) and use
considerable scheduled and unscheduled health care resources. I found that asthma
investigators used no consistent classification scheme for asthma severity, and the
level of agreement amongst specialists when categorizing patients with asthma was
low. Asthma severity has been classified using a wide range of parameters including
medication use, asthma symptoms, lung function, hospitalizations and incidence of
exacerbations. Most studies showed a general association between asthma severity
and health-related quality of life (HRQoL) such that patients with severe disease
suffered greater impairment. However, few patients with mild asthma enjoyed
unimpaired HRQoL. Indeed depression and impaired HRQoL were reported as
frequently in patients with mild asthma as in those with more severe disease.
Although in general severe patients used the most health care resources, even
patients with mild asthma used considerable health care resources including
emergency room care and hospitalizations. In summary, the term ‘mild’ when
applied to asthma is potentially misleading given the impaired HRQoL and avoidable
health care utilization prevalent amongst such patients. The application of disease
severity classification in clinical asthma management has not been validated. It may
now be appropriate to examine these classifications more critically in order to
determine if they have clinical or research usefulness. By contrast, the strategy
of treating to achieve disease control has been validated and offers the advantage of
simplicity in its application.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Worldwide, asthma is amongst the most common of
chronic diseases. In the United States, an estimated
17 million individuals are affected by the symptoms
and sequelae of asthma. The prevalence of asthma,
while relatively stable in some countries, is steadily
increasing in most developed nations.1–4 In devel-
oped countries, the prevalence of diagnosed
asthma in the adult population ranges from 2% to
19%.2,5,6 Most epidemiologic data do not distinguish
amongst categories of asthma severity, although it
is widely understood that the spectrum of asthma
severity, using conventional criteria, is highly
skewed; most patients have mild or very mild
disease, fewer have moderate disease and fewer
still have severe disease. European data suggest
that whilst asthma of all severities has increased
(comparing 1977–1992), the increase in prevalence
has been greatest amongst those considered to
have very mild-to-moderate disease.2 Moreover,
the prevalence of mild asthma may be under-
estimated; Tirimanna’s review showed that very
mild and mild asthma is often undiagnosed by the
primary care physician, whilst patients with severe
disease are invariably diagnosed.2
Asthma control may be defined in many ways, but
in clinical practice refers to the achievement of an
acceptable clinical state. Asthma control differs
from the assessment of disease severity, which
quantifies departure from ‘normal’. Numerous
national and international ‘asthma management’
guidelines have provided recommendations for the
control of the disease, emphasizing continuous
preventive care over symptom-driven and crisis
oriented care.7–11 According to the Global Initiative
for Asthma (GINA) guidelines,11 asthma is con-
trolled if patients have: minimal chronic symptoms
(including nocturnal symptoms); minimal or infre-
quent exacerbations of their asthma; no emer-
gency hospital visits; minimal (ideally no) use of
as-needed b2-agonists; no limitation to theiractivity levels (including exercise); peak expiratory
flow rate (PEF) circadian variation o20%; near
normal PEF; and minimal (or no) adverse effects
from medication. Other objective measures of
disease control currently being investigated include
airway hyperresponsiveness and markers of airway
inflammation.12 Despite the widespread accep-
tance of these guidelines, evidence from clinical
research indicates that many patients with asthma
are still not being adequately treated and overall
adherence to the guidelines is poor.13–16 Temporary
relief from, or absence of symptoms is not a
guarantee that the disease is controlled, and there
is evidence that the problem of inadequate or
intermittent treatment may be particularly com-
mon amongst patients with ‘mild’ disease.17 These
perspectives must be tempered by an awareness
that disease severity is often underestimated by
both physicians and patients.18
In addition to being one of the most important of
public health issues, asthma is also a major burden
on health care resources.11 The asthma burden
includes direct costs such as medication, medical
bills, clinic visits and hospitalization(s), and indir-
ect costs such as loss of productivity.19 Direct
health care costs have been shown to rise drama-
tically with more persistent and severe disease.19
Although patients with very severe asthma tend to
have worse health-related quality of life (HRQoL)
than patients with milder disease,20 only weak to
moderate correlations can be made between
conventional measures of clinical status and how
patients feel and function in everyday life.21 The
impact of asthma on HRQoL appears to decrease as
effective asthma control is achieved.22 Indeed, the
impact of asthma on HRQoL is minimal in many
patients with well-controlled disease.22
Guideline management tends to focus attention
on asthma of more than mild severity, but this
perspective may be short-sighted from the public
health and health care resources point of view.
Patients with severe disease tend to be recognized
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those with mild disease, and as a consequence
receive more attention and continuity of care. Yet
mild disease is more common and may be unrecog-
nized and under-treated. It is possible that asthma
interventions for mild and under-treated disease
could have greater impact than interventions for
known and treated severe disease. To help consider
this hypothesis more fully, this bibliographic review
assesses the available evidence relating to mild
asthma in order to evaluate the impact of such
asthma on HRQoL and level of health care resource
use.Methods
This review was designed to be as comprehensive as
possible with minimal bias regarding study identi-
fication and selection. All articles were required to
satisfy criteria of relevance to the research ques-
tion, patient population and language (Table 1).
The bibliographic search was run between JanuaryReject words/phrases 
with low recall or low 
precision
Identify k
and phr
search 
Reject articles not meeting 
inclusion/exclusion criteria on re-
application of the article criteria
Figure 1 Methods use to o
Table 1 Inclusion/exclusion criteria.
 Adult population
 English language
 Specific mention in the abstract that the study included d
 If it seemed likely the report might include information
asthma severity; (2) impact of mild asthma on health-re
resource use and indirect cost; and (4) impact of miscla1993 and August 2003. Although language restric-
tions may introduce some bias and limit the extent
and generalizability of the review, only English
language articles were included. Original clinical
research articles of any study design and review
articles were included. Single case reports were
excluded, as were articles where the abstract
specifically stated that the patients in the study
had only moderate and/or severe asthma. The
strategy for obtaining relevant articles is summar-
ized in Fig. 1.
To identify key words and phrases for the
bibliographic search, a broad list of terms used to
describe asthma and health outcomes was pro-
duced. Test searches were run on PubMed to
establish the recall and precision of various search
terms individually as text words or Medical Subject
Headings (MeSH) or in a number of combinations.
With this knowledge the search terms to be used for
electronic databases were identified (Table 2). I
chose a broad search strategy for asthma, not just
mild asthma, to ensure that relevant articles were
not missed.ey words 
ases for 
strategy
Select electronic 
databases to 
search
Undertake literature 
search on chosen 
electronic databases
Use article inclusion and exclusion 
criteria to select definite and possibly 
relevant articles
On receipt of the article, re-apply 
inclusion and exclusion criteria to 
select the relevant articles
btain relevant articles.
ata on patients stratified according to asthma severity
on one or more of four categories: (1) categorizing
lated quality of life; (3) impact of mild asthma on cost,
ssification on management
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Table 2 Medline search strategy.
1 (mild persistent asthma OR mild asthma OR milder asthma) AND quality of life
2 (mild persistent asthma OR mild asthma OR milder asthma) AND (resource use OR health economics
OR pharmacoeconomics OR burden)
3 (moderate asthma OR mild asthma OR milder asthma) AND (quality of life OR resource use OR health
economic OR pharmcoeconomic OR impact OR burden)
4 (moderate asthma OR mild asthma OR milder asthma) AND (quality of life OR resource use OR health
economic OR impact OR burden OR social cost)
5 (mild asthma OR moderate asthma) AND guideline
6 (mild asthma OR moderate asthma) AND (criteria OR diagnosis)
7 (mild asthma OR moderate asthma) AND (criteria OR diagnosis) AND (quality of life OR resource use
OR health economic OR impact OR burden OR social cost)
8 asthma AND quality of life
9 asthma AND (resource use OR health economics OR pharmacoeconomics OR burden)
10 asthma AND (quality of life OR resource use OR health economic OR impact OR burden OR social cost)
11 asthma AND guideline
12 asthma AND (quality of life OR resource use OR health economic OR impact OR burden OR social cost)
AND guideline
13 asthma AND (quality of life OR resource use OR health economic OR impact OR burden OR social cost)
AND guideline AND (criteria OR diagnosis)
14 asthma AND (quality of life OR resource use OR health economic OR impact OR burden OR social cost)
AND GINA
GINA, Global Initiative for Asthma.
Impact of mild asthma 1353An electronic database search is the only method
used for this review. Hand searching, scanning
reference lists, grey literature and conference
proceedings were not included. No database is
complete, so two databases were chosen to extend
coverage: (1) Medline (Index Medicus online) and
(2) EMBASE (Excerpta Medica online). Medline and
EMBASE provide coverage of the literature in many
health care areas but do not record all publications
from all medical journals. Medline is the most
comprehensive health care research database,
providing a wide coverage of many English language
journals; EMBASE contains more European journals
than Medline.
All titles and abstracts obtained from the search
were scanned manually, and full articles were
retrieved following the application of the inclu-
sion/exclusion criteria. Since it is not always
possible to be certain of the relevance of the
article based purely on the search results, articles
of definite and possible relevance were retrieved in
full and then the article inclusion/exclusion criteria
were re-applied to the full article.Results
Of a total of 5600 titles and abstracts retrieved
electronically, 389 articles were considered to be
either possibly or definitely relevant. These articleswere reviewed in full and reassessed against the
inclusion/exclusion criteria. Thirty-nine articles
met the inclusion/exclusion criteria for this mild
asthma outcomes bibliographical review.
The results of the bibliographic review were
divided into four main categories according to
article content: (1) categorizing asthma severity;
(2) impact of mild asthma on HRQoL; (3) impact of
mild asthma on cost, health care resource use and
indirect cost; and (4) impact of misclassification on
management. Table 3 summarizes the key messages
of each of the four categories. Fig. 2 summarizes
the bibliographic search and lists the number of
articles assigned to each category. Some articles
could be included in more than one category.
Twenty-three articles examining the impact of mild
asthma on HRQoL and/or health care resource
utilization were identified.Categorizing asthma severity
Although it is common to classify patients by
asthma severity for either clinical or research
purposes, there is no universal severity classifica-
tion scheme adopted by practitioners and research-
ers. Over the years asthma severity has been
defined using a diverse range of parameters and
strategies. This point is highlighted by the different
definitions of mild asthma encountered in both the
HRQoL and the health care resource articles
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Category Key messages
K.R. Chapman1354identified in this bibliographic review. Mild asthma
was defined according to: medication use23–25;
the presence and/or frequency of asthma symp-Table 3 Key message summary.
Category Key messages
Categorizing
asthma severity
 Substantial numbers of
patients diagnosed with
mild asthma are
misclassified and under-
treated
 A substantial number of
patients diagnosed with
mild asthma by GINA
criteria may fall into a
higher treatment step
based on current
medication usage
 For patients with
inadequate symptom
control, lower physician
estimates of underlying
severity are associated with
care that is less consistent
with national guidelines
 Patients often
underestimate the severity
of their disease and are
therefore at risk of under-
treatment
 Agreement between
specialists on classification
of severity is low
Impact of mild
asthma on HRQoL
 QoL is poorer for individuals
with more severe asthma,
but the numbers of
individuals with good/fair
and poor/very poor QoL are
substantial in the ‘mild
intermittent’ and ‘mild
persistent’ classes
 QoL scores are significantly
different for all severity
stages and all domains;
however, discriminate
factor analysis does not
indicate a strong
relationship between QoL
and severity
 Emotional role and mental
health scores are slightly
worse for patients with
mild rather than moderate
asthma
 It is possible to improve
QoL, even in patients with
mild asthma
 QoL results do depend on
instruments used
Impact of mild
asthma on cost,
health care
resource use, and
indirect cost
 The use of emergency care
is nearly as great in
patients with mild asthma
compared to those with
more severe disease
 Productivity loss (in terms
of days missed from work)
can be greatest in the mild
intermittent class
 Medical resource utilization
is greatest in patients with
poor control and moderate
disease severity
 Mild asthma can be
associated with higher
costs for consultations and
supplementary
examinations
 Patients with mild asthma
are also referred to the
emergency department due
to exacerbations
Impact of
misclassification
asthma on
management
 Many patients with mild
asthma have not received a
diagnosis of asthma and are
therefore under-treated
 Patients with more severe
disease (according to
physician assessments) are
more likely to receive care
consistent with guidelines
 Of patients diagnosed with
mild asthma, many receive
treatment that is
inadequate according to
guidelines
 Reliever medication use
relative to controller
medication use is
approximately the same for
all severity categories
 Many patients with mild
asthma have never had
their lung function
measured, owned a PEF
meter, had their PEF
measured during their most
recent exacerbation, or
know their best PEF
GINA, Global Initiative for Asthma; HRQoL, health-related
quality of life; PEF, peak expiratory flow; QoL, quality of
life.toms26–31; or lung function parameters.32,33 More
complex definitions of mild asthma incorporated a
composite of two or more parameters in various
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n=5 
categorizing 
asthma 
severity 
5600 articles identified 
from initial broad 
search Articles accepted or 
discarded based on 
application of 
inclusion/exclusion criteria 
(see Table 1)389 articles selected 
which were definitely 
or possibly relevant
Articles accepted or 
discarded based on re-
application of 
inclusion/exclusion criteria 
(see Table 1)
39 articles selected for 
bibliographic review
n=12 
impact on 
health-
related 
quality of 
life 
n=13 
impact on 
cost, 
resource 
use and 
indirect cost
n=18 impact of 
misclassification 
on management 
Figure 2 Bibliographic search results (Some articles
appear in more than one category).
Impact of mild asthma 1355combinations such as lung function, presence of
symptoms, medication use, inhaled corticosteroid
(ICS) dose, hospitalizations and incidence of ex-
acerbations.13,34–40 Asthma management guidelines
were used by authors in only three articles.41–43
Table 4 summarizes each article according to how it
defined ‘mild’ asthma. For the purposes of this
review, no attempt was made to reconcile these
various classification schemes, and disease severity
was accepted as determined by the authors’ criteria.
A subset of articles considered the impact of
being inappropriately categorized with mild asth-
ma. Identified consequences of being inappropri-
ately categorized with mild asthma included under-
medication, inadequate symptom control, and not
being treated according to asthma management
guidelines.44,45 Physician estimates of underlying
asthma severity appear to determine asthma care
for patients if considered as mild.45 Patients with
inadequate symptom control and lower physician
estimates of asthma severity were associated with
care which was less consistent with national asthma
management guidelines.45 A study carried out in
Belgium revealed that general practitioners (GPs)
tend to assess asthma severity based on patients’
daytime symptoms rather than adhering to the
severity classification advocated in the GINA guide-
lines.44 Therefore, a high proportion of patients
(20%) were classified by GPs as having mild asthma
according to their medication usage, when they
should have been in a higher severity category. As aresult 73.4% and 60.1% of patients with mild
intermittent asthma and mild persistent asthma
respectively were under-treated due to inadequate
assessment of asthma severity.44 Patients them-
selves can also underestimate the severity of
their disease and are therefore at risk of under-
treatment.46
Furthermore, agreement between specialists on
categorizing severity seems to be low.47 Three
pulmonary specialists extracted clinical findings
from out-patient progress notes. They correctly
identified the need for inhaled anti-inflammatory
agents 76% of the time, but agreed on severity
classification in only 57% of the cases.47 The GINA
guidelines have been widely used to assess asthma
severity. However, these guidelines were not
designed for that purpose, but rather to describe
the recommended therapy for asthma of different
severities. Therefore, a substantial number of
patients diagnosed with intermittent and mild
persistent asthma by GINA criteria may fall into a
higher treatment step based on current medication
usage.48 As many as 40% of patients with inter-
mittent asthma and 30% of patients with mild
persistent asthma were misclassified according to
the GINA guidelines and should have been in a
higher severity category based on a final symptom –
forced expiratory volume in 1 s (FEV1) medication
classification.48
Fuhlbrigge and colleagues27 showed that the
categorization of severity is also greatly influenced
by the type of symptom reports used in a
classification system. Evaluation of specific day-
and night-time symptoms alone may underestimate
the impact of asthma on patients’ lives. In
addition, patients’ failure to communicate the
impact of the disease on their daily activities may
contribute to the discordance observed in symptom
reports. Indeed, correlation between physician-
assessed severity and level of current asthma
symptoms is poor. These difficulties experienced
by both patients and physicians in recognizing
asthma severity, together with the associated
problems of under-treatment, may contribute to
the high level of asthma burden currently observed.Impact of mild asthma on health-related
quality of life
A wide range of patient-assessed health outcome
instruments have been used to assess the HRQoL
in patients with mild asthma. Some of these
are respiratory or asthma-specific, such as the
St. George’s Respiratory Questionnaire (SGRQ),
the Asthma Quality of Life Questionnaire (AQLQ),
ARTICLE IN PRESS
Table 4 Mild asthma definition summary.
Mild asthma definition Reference
Based on medication 22
NAEPP 1997 25,26,29,34,60
Åas score and self-defined 56
GINA 1995 43,47,61,63
Based on NAEPP 1991 40,44
VAS scale from ‘no problems at all’ to ‘problems so bad that I have to be admitted to hospital’ 33
Self-developed and validated assessment 37
NHLBI 1993; NAEPP 1993 46
NHLBI 1993; International Consensus Report 1992 57
Australian Asthma Management Guidelines 41
Adaptation of NAEPP 1997 38,62
Based on symptoms, PEF, medication use 48
Based on symptoms, hospitalization and intubation for asthma; medication 35
FEV1 measurements defined by ATS 1987
31
BTS 1993 32
Based on medication 23
Based on symptoms; severe episodes 17
ICG 1992 12,58
NAEPP 1997; ATS 1993 45
Based on medication (NAEPP 1997) 59
FEV1 and symptoms
27
Nocturnal symptoms and quality of life 30
Based on medication; GINA 1995 and the Danish list of pharmaceuticals 39
Nurse-assigned severity; NHLBI guidelines 42
GINA-derived algorithm (control) 24
FEV1 measurements defined by ATS 1987
65
ICG 1992; BTS 1993 36
Combination of symptoms 28
ATS: American Thoracic Society; BTS: British Thoracic Society; FEV1: forced expiratory volume in 1 s; GINA: Global Initiative for
Asthma; ICG: International Consensus Guidelines; NAEPP: National Asthma Education and Prevention Program; NHLBI: National
Heart Lung and Blood Institute; PEF: peak expiratory flow; VAS: visual analogue scale.
K.R. Chapman1356the Marks Asthma Quality of Life (MAQoL) ques-
tionnaire, and the Hyland QoL questionnaire. The
main advantage of these instruments is that they
have relevant content when used in trials for
asthma and are likely to be sensitive to change in
the condition over time. In addition, when using
these instruments, completion rates and question-
naire acceptability are high as the questionnaire
items have clear relevance to the patient popula-
tion with the disease. However, these specific
instruments may not capture unexpected health
problems associated with a disease and its treat-
ment. The most salient disadvantage is that they do
not allow for comparison between outcomes of
different treatments for different diseases for
purposes of resource allocation. Generic instru-
ments, such as the 15D, the short-form 36 (SF-36),
the Nottingham Health Profile (NHP), and the
Sickness Impact Profile (SIP) have also been used
in the study of asthma patients. These question-
naires cover a broad range of aspects of HRQoL.They are not age-, disease- or treatment-specific
and contain multiple HRQoL concepts of relevance
to patients and the general population, enabling
comparisons across diseases using reference values
for a general population. Because these generic
instruments are broad in scope, they have value in
detecting unexpected positive or negative effects
of an intervention. A key problem with these
instruments is that they contain fewer relevant
items to a particular disease compared to disease-
specific questionnaires, and so they are less likely
to detect relatively small changes in health status.
They can also contain irrelevant items and miss
important aspects.
In general, patients with mild asthma have been
found to have a better asthma-specific HRQoL
compared with those patients with more severe
disease.26,28,34 However, not all patients with mild
asthma have a good HRQoL. Fuhlbrigge and
colleagues27 found that a high proportion of
patients with mild asthma had a poor HRQoL
ARTICLE IN PRESS
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asthma. Similarly, although Viramontes et al.29
found that most SF-36 scores were better for
patients with mild asthma, the emotional role and
mental health scores were worse compared with
patients in a higher severity class. Indeed, moods
such as sadness, depression and frustration may be
similar in all patients regardless of the severity of
the disease.23 This means that patients with mild
disease can be just as depressed and frustrated
with their disease as patients with more severe
asthma. Others have concluded that patients with
mild asthma may have similar HRQoL impairment to
patients with severe asthma.35
Many patients with asthma perceive their disease
to be mild or very mild.26 This misperception of
asthma severity and of the level of asthma control
can affect HRQoL, since greater perceived asthma
control is associated with less severe asthma and
better asthma-specific HRQoL.36 Impaired HRQoL in
mild asthma can be inferred by the improvement
seen in even mild asthma by appropriate ther-
apy.32,33,37,49 For example, patients with mild
asthma treated with beclomethasone dipropionate
(BDP) via Easyhalers or metered dose inhaler (MDI)
showed an improvement in asthma-specific HRQoL
as measured by the SGRQ.33 Similarly, adding
salmeterol or BDP to existing low dose ICS also
improved the HRQoL of mild asthmatic patients.37
When measuring HRQoL, it is important to
consider that results may be affected by the choice
of instrument. Some authors have recommended
that the optimal strategy is to use a combination of
generic and specific instruments in a study.50,51 The
main reason for this approach is that the two kinds
of measure are likely to produce complementary
evidence, detecting unexpected positive or nega-
tive effects of treatment, if present, as well as
being relevant and responsive to changes in health
for the particular disease. However, this strategy
does impose a greater burden on patients which
may reduce compliance and also increases the
number of statistical analyses and hence the
possibility of effects arising by chance. Kauppinen
and colleagues32 compared the generic 15D with
the disease-specific SGRQ and showed that these
two instruments did not completely agree with
each other when used to estimate the effectiveness
of an asthma intervention. In fact, the tools agreed
on the direction of HRQoL change in only 64.8% of
cases. The SGRQ indicated more positive changes
and less negative changes than the generic 15D,
and showed better agreement with clinical severity
variables.32 Panel data model analysis revealed
that age, gender and smoking habit significantly
affected the relationship between the SGRQ and15D. Others have previously shown that socio-
demographic factors, such as age and education,
may influence the relationship between HRQoL
tools.52,53 Godard and colleagues35 also showed
that the SGRQ was more responsive to change in
HRQoL than the SIP.
Some HRQoL instruments do show good agree-
ment. Sanjuas and co-workers28 directly compared
the applicability and metric properties of the two
specific instruments, the AQLQ and SGRQ, in
asthma patients with a broad range of disease
severity, and showed no relevant differences
between them. However, the symptoms subscale
of the SGRQ did not show an appropriate long-
itudinal validity or sensitivity to change, possibly
due to the combination of symptom items covering
both asthma and COPD. In addition, the AQLQ was
more precise than the SGRQ in discriminating
among severity levels based on patients’ clinical
setting and frequency of symptoms, whereas the
SGRQ showed higher cross-sectional correlations
with FEV1.
28Impact of mild asthma on cost and health
care resource use
In general, the severity of asthma is associated with
the level of health care resource use and costs
incurred.13,24–27,35,38–41,43 Costs are incurred directly
based upon use of these health care resources, and
also indirectly as assessed by lost productivity and
days absent from work due to asthma.27,37,42
Resources used by patients with asthma fall broadly
into four categories: medication used25,41,43; days
spent in hospital24,25,39; emergency department or
out-patient visits13,25,27,39; and consultations/sup-
plementary examinations.25,35 Other health care
resources used include ambulance and other trans-
portation, paid help for housekeeping, peak flow
meters and alternative treatment/medication. Tink-
leman et al.43 found that the patients most likely to
use health care resources are females under 44
years old who have used oral corticosteroids in the
past, have a high level of day- and night-time
symptoms, did not graduate from high school and
are unemployed due to their asthma.Direct costs
In France, total direct costs ranged from h263 per
patient per year for mild intermittent asthma, h686
for mild persistent, h1196 for moderate persistent,
to h2782 for severe persistent asthma.35 Although
no patients with mild intermittent or mild persis-
tent asthma in that study were hospitalized, mild
asthma was associated with higher costs for
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than any other severity stage35; the proportion of
costs associated with consultation were almost
twice as high for patients with mild intermittent
disease. Another French study which specifically
examined the relationship between asthma sever-
ity/control and health care resource use in patients
across the severity range showed that patients of
all asthma severities can have poorly controlled
disease, and it is these patients who are inade-
quately controlled who use the most health care
resources. The mean total direct costs per patient
per year for ‘low’ severity asthma were h559,
versus h943 and h772 for ‘moderate’ and ‘high’
categories.25 The classification of asthma severity
used in that study was based on ICS dose rather
than the composite definition based on lung
function/short-acting b2-agonist use/symptoms
and medication which was used in the Godard
study.35 A Danish study reported that the total
direct cost for mild intermittent patients was 1176
DKR, and 7899 DKR for mild persistent disease.40
Drugs account for a large proportion of the direct
costs of asthma. A study carried out by Diette and
colleagues41 showed that the majority of mildly
asthmatic patients report using one or two types of
medication compared with two or three types of
medication for patients with moderate or severe
asthma.41 b2-agonists were by far the most com-
monly used medication for mild patients, and only
3.6% of mild patients were considered to overuse
this medication. However, that study was per-
formed before the release of the 1997 NAEPP
guidelines and so a greater proportion of these
patients might now be considered b2-agonist over-
users, hence incurring more costs. 10.1% of mild
asthma patients reported using no medication.41
Although patients with mild asthma use fewer
medication types, they have been reported to use
almost as much reliever and controller medication
as patients with moderate or severe persistent
disease.27 The capacity to afford medication often
determines patients’ treatment choices and con-
founds assessment of health care utilization by
severity.42 Due to cost considerations, patients
often lower the dose of their medication or do
not take it at all; this is a false economy, resulting
in increased GP and out-patient visits as well as
increased hospitalizations.
A substantial proportion of mild asthma patients
present at emergency and out-patient hospital
departments13,39 and are seen by consultants/
GPs, thereby increasing costs.35,39 Hartert and
colleagues39 showed that 44% of patients with
intermittent asthma attended an out-patient de-
partment in the 14 days prior to study entry andhad out-patient visits on 12 occasions in the past
year. All mild asthma patients recruited in another
study13 were reviewed monthly by their GP and 25%
of them had been referred on more than two
occasions to the emergency department because of
exacerbations in the past year. Indeed, use of
emergency care may be almost as high in patients
with mild persistent asthma as in those with
moderately severe persistent disease.27
The risk of hospitalization for patients with
asthma is imperfectly associated with disease
severity.38 Overall costs are higher in patients
receiving poor treatment and with more severe
disease.40 However, the rate of hospitalization in
patients considered to have mild disease was
estimated at 92–133 bed days per 1000 patients,
compared with 156–277 bed days for patients with
more severe disease.24 Other factors that may
affect the use of health care resources in patients
with asthma include: use of oral corticosteroids,
frequency of day- and night-time symptoms,
patient age, gender, educational level and employ-
ment status.43
Indirect costs
Indirect costs are reportedly higher than direct
costs, with days lost from work representing the
main indirect costs of asthma. To the employer,
absenteeism and performance have important
implications to overall productivity and costs. A
Danish study revealed that the annual indirect cost
of asthma associated with sick leave was 2005 DKR
per patient, and that the cost of taking early
retirement was a massive 29,239 DKR.40 Some
studies revealed that mild asthma patients lost
hardly any days from work,35 whereas others
showed that as many as 11.3% of mild asthma
patients missed one or more days work due to their
asthma.26 Increasing asthma severity is also asso-
ciated with a decline in perceived work perfor-
mance.26,42 However, when severity was classified
according to ‘symptoms experienced’ rather than
‘perceived severity’, patients with mild asthma had
a similar perceived work performance compared
with moderate asthma patients.
The two most economically important conse-
quences of asthma, including mild asthma, are
hospitalizations and lost production due to illness
and retirement. These costs may be reduced by
improving asthma treatment, by the provision of
sufficient medication and by education to improve
compliance. Effective asthma control reduces
costs, particularly by decreasing hospitaliza-
tions.54,55 If national guidelines for the manage-
ment of asthma were followed it is likely that the
number of hospitalizations would fall.56
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Despite advances in the diagnosis of asthma and the
wide-spread dissemination of asthma management
guidelines, many patients (almost 70%) with mild
asthma have not received an official diagnosis.57 Of
asthma patients diagnosed as mild, many are
treated inadequately, not according to guide-
lines.13,27,35,39,58–64 Ferrante and colleagues58 re-
ported that a high number of mild asthma patients
were not taking any medication. Of those using
medication, more than 50% were under-treated
with steroids and more than 25% were under-
treated with b2-agonists.
59 Maintenance therapy
results were worst in Italy where 76% of mild
asthma patients were on inadequate concentra-
tions of inhaled steroids compared with 24% in
Slovakia and 9% in Norway.60 Indeed, use of
controller medication was about half as common
in the mild intermittent class as in the other
classes.27 Reliever medication use relative to
controller medication use was about the same for
all severity categories, indicating that the fre-
quency of exacerbations (i.e. lack of disease
control) is as high in individuals with milder disease
as in those with more severe disease.27
Adherence to asthma medication guidelines is
poor for mild persistent asthma patients. Patients
with more severe disease as assessed by a physician
are more likely to receive care that is consistent
with guidelines.45 Barr and colleagues61 showed
that only 57% of patients with mild asthma adhered
to asthma medication guidelines.61 In an Italian
study carried out in 1998, approximately 45% had
mild persistent asthma, but only 16% were using
ICSs as recommended by the GINA guidelines.62 One
of the goals of the GINA guidelines is to achieve
normal or near normal lung function. However,
many mild asthma patients have never had their
lung function measured,18 and are likely never to
have owned a PEF meter, not know their best PEF,
or not had their PEF measured during their most
recent exacerbation.13 Mild asthma patients also
made more errors in inhaler technique than other
severity groups and frequently did not have an
action plan to follow if their symptoms of asthma
worsened.13
Bearing in mind that many mild asthmatic
patients are under-treated, the effects of various
treatment regimens in this patient population have
been investigated.37,65,66 Vermetten and collea-
gues37 studied patients with mild asthma who were
already on low-dose steroids and showed that
control can be improved in these patients. Simi-
larly, Morice and co-workers65 found that initiation
of treatment with anti-inflammatory therapy pro-duced the greatest symptomatic and physiological
improvements in mild asthma. Continuous use of
bronchodilators over 4 years in patients with non-
steroid-dependent asthma or chronic bronchitis
does not lead to declined lung function, which
was observed previously in patients with moderate
asthma or chronic bronchitis during 2 years of
continuous treatment with bronchodilators.66Discussion
This systematic analysis of the asthma severity
literature has shown that asthma investigators use
no consistent classification scheme for asthma
severity and no consistent definition of mild
asthma. The various classification criteria that
have been used would appear to have some
validity. In most studies, for example, there
appeared to be a rough association between
asthma severity and HRQoL such that patients with
severe disease tended to have more impairment
than patients with mild disease. Nonetheless, there
was considerable overlap amongst groups, and in
some studies depression and impaired quality of life
(QoL) were seen as frequently in patients with mild
asthma as in patients with more severe disease.
Few patients with mild asthma enjoy unimpaired
QoL, and in some studies impairment in mild
asthma has been similar to that seen in severe
asthma. Similarly, there was a rough association
between investigator defined disease severity and
health care utilization. Nonetheless, even patients
with mild asthma used considerable health care
resources including inpatient resources such as the
need for emergency room care or hospitalization.
The ability of altered therapy to improve QoL and
reduce health care utilization in mild asthma
suggests that substantial treatable impairment
exists.
The marked impact of putatively mild asthma on
HRQoL would at first glance appear counter-
intuitive. This review found that mild asthma has
a disproportionately high impact on HRQoL in that
patients with mild asthma can suffer impairment in
HRQoL equal to or greater than that suffered by
patients with more severe disease. Indeed, moods
such as sadness, depression and frustration are
similar in all groups of asthma patients regardless
of the severity of their disease. I believe that these
findings reflect two or three phenomena. First,
patient QoL is likely a reflection of actual impair-
ment compared to patient expectations. Although
patients with apparently mild disease may have less
frequent episodes of wheezing or less airflow
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patients who regard themselves as having mild
disease are likely to have higher expectations for
unimpaired QoL. Second, patients may evaluate
their QoL against experiential reference points. For
example, patients who have suffered with more
frequent and severe episodes of disease may regard
the period between exacerbations as more toler-
able or less impaired than patients who lack such
experience. Finally, as I have noted, classification
schemes for asthma severity are variable and
inconsistently applied. Patients regarded as having
mild disease by an unvalidated set of criteria may
have intrinsically more severe disease. In addition,
the asthma severity may vary over time such that
apparently mild asthma at the time of diagnosis or
recruitment into a trial may be more severe
subsequently. An alternative argument for the
minimal of difference in HRQoL amongst severity
groups would be inadequacy of the instrument used
to measure HRQoL. I think this is unlikely as the
minimal difference in HRQoL amongst severity
groups has been found using several different
validated instruments responsive to changes in
therapy.
Patients with putatively mild asthma use health
care resources disproportionately to their apparent
disease severity. For example, patients with mild
persistent asthma may make almost as much use of
emergency care as patients with moderately severe
persistent disease.27 Mild asthma is also associated
with poor productivity (absenteeism from work)
and higher costs for consultations and supplemen-
tary examinations than any other severity stage.
Such findings suggest that the use of the term mild
may be counterproductive from the societal per-
spective if it encourages under-treatment or inter-
mittent treatment. Patients with nominally mild
asthma account for the largest portion of the
asthma population, and even a slightly lower health
care utilization rate per capita becomes a large
number of emergency room visits and hospital stays
when multiplied by prevalence. Moreover, it is
likely that such health care utilization is more
easily avoided in patients regarded as having mild
disease; for some patients with severe disease,
exacerbations may be comparatively difficult to
prevent.
Classification schemes for asthma severity have
been used by investigators and have been incorpo-
rated into guideline documents with relatively
little debate or discussion. It may now be appro-
priate to examine these classifications more criti-
cally in order to determine if they have clinical or
research usefulness. Available evidence shows that
classifications of disease severity may be internallyinconsistent, may produce discordant results even
when applied by specialists and are unlikely to be
applied by primary practitioners particularly if lung
function measurements are required. The present
review shows that patients thought to have mild
asthma often suffer impairment in QoL and use
considerable health care resources. The foregoing
facts suggest that the process of estimating disease
severity at the time of diagnosis and treating
according to this estimate is a flawed clinical
strategy. A more productive paradigm is basing
treatment upon assessments of control. Patients
with uncontrolled disease receive optimal therapy
designed to control disease as quickly and com-
pletely as practical. Amounts of medication are
subsequently stepped down until the minimum
amount of medication needed to maintain control
is determined. Such ‘step down’ approaches have
been described in guideline documents, but their
use appears to have been confounded by confusion
over severity versus control assessments.
In summary, the term ‘mild’ when applied to
asthma is potentially misleading given the impaired
QoL and avoidable health care utilization prevalent
amongst such patients. The application of disease
severity classification in clinical asthma manage-
ment is unvalidated. By contrast, the strategy of
treating to achieve disease control has been
validated and offers the advantage of simplicity in
its application.References
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